EUVIMEDEUVIMED entdecken
Crossref

Discovery of GPR84 Fluorogenic Probes Based on a Novel Antagonist for GPR84 Bioimaging

Yufeng Xiao, Jing Chen, Shaoxian Li, Qing Zhang, Yin Liu, Linhai Chen iD, Yadi Sun, Min Gu, Xin Xie, Fajun Nan iD

Journal of Medicinal Chemistry · 2024

DOI: 10.1021/acs.jmedchem.4c00359 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2024. Verfasst von Yufeng Xiao und 9 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Drug Research, National Center for Drug Screening, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shangha…. Hauptthemen laut MEDLINE: Receptors, G-Protein-Coupled, Fluorescent Dyes. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: Youth Innovation Promotion Association of the Chinese Academy of Sciences, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

GPR84 is a promising therapeutic target and biomarker for a range of diseases. In this study, we reported the discovery of BINOL phosphate (BINOP) derivatives as GPR84 antagonists. By investigating the structure-activity relationship, we identified 15S as a novel GPR84 antagonist. 15S exhibits low nanomolar potency and high selectivity for GPR84, while its enantiomer 15R is less active. Next, we rationally designed and synthesized a series of GPR84 fluorogenic probes by conjugating Nile red and compound 15S. The leading hybrid, probe F8, not only retained GPR84 activity but also exhibited low nonspecific binding and a turn-on fluorescent signal in an apolar environment. F8 enabled visualization and detection of GPR84 in GPR84-overexpressing HEK293 cells and lipopolysaccharide-stimulated neutrophils. Furthermore, we demonstrated that F8 can detect upregulated GPR84 protein levels in mice models of inflammatory bowel disease and acute lung injury. Thus, compound F8 represents a promising tool for studying GPR84 functions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, G-Protein-CoupledFluorescent DyesHumansAnimalsHEK293 CellsStructure-Activity RelationshipMiceMice, Inbred C57BLDrug DiscoveryLipopolysaccharides

Substanzen

Receptors, G-Protein-CoupledFluorescent DyesGPR84 protein, humanLipopolysaccharides

Autor:innen und Institutionen

  • State Key Laboratory of Drug Research, National Center for Drug Screening, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
  • University of Chinese Academy of Sciences, Beijing 100049, China.
  • School of Pharmaceutical Science and Technology, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou 310024, China.
  • Shandong Laboratory of Yantai Drug Discovery, Bohai Rim Advanced Research Institute for Drug Discovery, Yantai 264117, Shandong, China.
  • School of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing 210023, China.

ORCID-Profile: Linhai Chen, Fajun Nan

Förderung

  • Youth Innovation Promotion Association of the Chinese Academy of Sciences
  • National Natural Science Foundation of China

Zitieren

APA

Xiao, Y., Chen, J., Li, S., Zhang, Q., Liu, Y., Chen, L., Sun, Y., Gu, M., Xie, X., & Nan, F. (2024). Discovery of GPR84 Fluorogenic Probes Based on a Novel Antagonist for GPR84 Bioimaging. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c00359

Vancouver

Xiao Y, Chen J, Li S, Zhang Q, Liu Y, Chen L, et al. Discovery of GPR84 Fluorogenic Probes Based on a Novel Antagonist for GPR84 Bioimaging. Journal of Medicinal Chemistry. 2024. doi:10.1021/acs.jmedchem.4c00359

BibTeX
@article{Xiao2024,
  author = {Xiao, Yufeng and Chen, Jing and Li, Shaoxian and Zhang, Qing and Liu, Yin and Chen, Linhai and Sun, Yadi and Gu, Min and Xie, Xin and Nan, Fajun},
  title = {Discovery of GPR84 Fluorogenic Probes Based on a Novel Antagonist for GPR84 Bioimaging},
  journal = {Journal of Medicinal Chemistry},
  year = {2024},
  doi = {10.1021/acs.jmedchem.4c00359}
}
Kostenlos starten →